The reintroduced Humane Cosmetics Act may again face an uphill battle, despite support from both sides of the aisle, given competing administration priorities and continuing uncertainties on substantiating product safety without FDA’s acceptance of certain alternative tests.
The bill will likely not be a priority following President Trump’s vow to cut regulations, though industry is hoping the...